# A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy

> **NCT05276297** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 174 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** GSK3228836
- **BIOLOGICAL:** GSK3528869A
- **DRUG:** Control

## Key facts

- **NCT ID:** NCT05276297
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-22
- **Primary completion:** 2025-08-05
- **Final completion:** 2025-08-05
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05276297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05276297, "A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05276297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*